Table 2 Model Costs, Utility estimates and other parameters

Treatment costs

 cemiplimab (per 1 mg)

Uniform

27.231 (20.423—27.231)

[15]

 paclitaxel (per 1 mg)

Normal

0.115 (0.086—0.144)

[15]

 carboplatin (per 50 mg)

Normal

2.483 (1.862—3.104)

[15]

 cisplatin (per 10 mg)

Normal

1.692 (1.269—2.115)

[15]

 pemetrexed (per 10 mg)

Normal

27.681 (20.761—34.601)

[15]

 Administration (first hour)

Normal

140.16 (105.12—175.2)

[17]

 Administration (additional hour)

Normal

29.76 (22.32—37.2)

[17]

 Disease management (per cycle in the stage of PF)

Normal

441.75 (331.31—552.19)

[19]

 Disease management (per cycle in the stage of PD)

Normal

1,374 (1,030.5—1,717.5)

[19]

 Best supportive care (per cycle)

Normal

2,286.75 (1,715.06 – 2,858.44)

[16]

 Palliative care

Normal

12,679.54 (9,509.66 – 15,849.43)

[18]

Expenditure of AEs management

 Neutropenia

Normal

14,906.47 (11,179.85 – 18,633.09)

[20]

 Anemia

Normal

8,667.64 (6,500.73 – 10,834.55)

[20]

 Thrombocytopenia

Normal

14,304.96 (10,728.72 – 17,881.2)

[20]

Utility estimates

 Progression-Free Disease

Beta

0.70 (0.525—0.875)

[22]

 Progressive Disease

Beta

0.58 (0.435—0.725)

[22]

Other parameters

 Body surface area, m²

Normal

1.79 (1.34–2.24)

[16]